SLN Silence Therapeutics Plc

Price (delayed)

$6.82

Market cap

$321.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.62

Enterprise value

$316.3M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 20

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform ...

Highlights
The equity has soared by 56% YoY and by 21% from the previous quarter
Silence Therapeutics's gross margin has increased by 29% QoQ and by 18% YoY
Silence Therapeutics's debt has soared by 127% YoY but it has decreased by 15% from the previous quarter
SLN's revenue has plunged by 97% YoY but it has soared by 50% from the previous quarter

Key stats

What are the main financial stats of SLN

SLN stock price

How has the Silence Therapeutics stock price performed over time
Intraday
6.4%
1 week
-0.58%
1 month
-6.45%
1 year
24%
YTD
12.17%
QTD
29.41%

Financial performance

How have Silence Therapeutics's revenue and profit performed over time
Revenue
$839,000
Gross profit
$667,000
Operating income
-$78.41M
Net income
-$75.04M
Gross margin
79.5%
Net margin
-8,943.9%
SLN's revenue has plunged by 97% YoY but it has soared by 50% from the previous quarter
The gross profit has plunged by 96% YoY but it has soared by 94% from the previous quarter
Silence Therapeutics's net margin has increased by 44% from the previous quarter
The operating margin is up by 43% since the previous quarter

Price vs fundamentals

How does SLN's price correlate with its fundamentals

Growth

What is Silence Therapeutics's growth rate over time

Valuation

What is Silence Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
383.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
376.99
Silence Therapeutics's EPS has increased by 14% QoQ but it has decreased by 8% YoY
The equity has soared by 56% YoY and by 21% from the previous quarter
SLN's revenue has plunged by 97% YoY but it has soared by 50% from the previous quarter
The P/S is 74% higher than the last 4 quarters average of 207.3

Efficiency

How efficient is Silence Therapeutics business performance
SLN's ROA has plunged by 57% YoY but it is up by 4.8% from the previous quarter
Silence Therapeutics's return on sales has increased by 44% QoQ
SLN's ROIC is up by 15% from the previous quarter but it is down by 4.9% YoY

Dividends

What is SLN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLN.

Financial health

How did Silence Therapeutics financials performed over time
The total assets is 75% more than the total liabilities
The total assets has contracted by 38% YoY and by 12% from the previous quarter
Silence Therapeutics's current ratio has increased by 13% from the previous quarter and by 12% YoY
Silence Therapeutics's debt is 100% more than its equity
Silence Therapeutics's debt has soared by 127% YoY but it has decreased by 15% from the previous quarter
The equity has soared by 56% YoY and by 21% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.